Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 970 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride Injection Clear all
Completed Phase 1 Interventional

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT01835730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
PE0139 Injection, Placebo
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Anniston, Alabama • Hialeah, Florida • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 4, 2026, 8:52 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

NCT02035605
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 1Phase 2 Interventional

Joint Injections for Osteoarthritic Knee Pain

NCT00085722
View directory record Official record
Conditions
Osteoarthritis
Interventions
Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302
View directory record Official record
Conditions
Inflammatory Response
Interventions
Pneumovax 23, Typhim VI, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Not applicable Interventional

Medial Branch Blocks vs. Intra-articular Injections: Randomized, Controlled Study

NCT02002429
View directory record Official record
Conditions
Lumbar Facet Joint Pain, Low Back Pain
Interventions
Intra-articular injection, Medial branch block, Saline injection
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 4, 2026, 8:52 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2

NCT02704325
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
rAAVrh74.MCK.GALGT2, PLACEBO (Saline)
Biological · Other
Lead sponsor
Kevin Flanigan
Other
Eligibility
9 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

NCT01753076
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ozanezumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Determine if Caffeine Accelerates Emergence From Anesthesia

NCT02567968
View directory record Official record
Conditions
Anesthesia
Interventions
Caffeine, Placebo Control
Drug
Lead sponsor
University of Chicago
Other
Eligibility
25 Years to 40 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

NCT02556710
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
4 mL injection of AMPION™, 4 mL injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 4, 2026, 8:52 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

NCT02679274
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Galveston, Texas • Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
View directory record Official record
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 4, 2026, 8:52 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

NCT03150420
View directory record Official record
Conditions
Calciphylaxis
Interventions
Sodium Thiosulfate, Placebo-Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Jacksonville, Florida • Chicago, Illinois • Maywood, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 4, 2026, 8:52 PM EDT
Terminated Phase 2 Interventional

Plasma Injections Plus Exercise for Patellar Tendinopathy

NCT02116946
View directory record Official record
Conditions
Patellar Tendinopathy
Interventions
Platelet Rich Plasma (PRP), Saline + exercise
Biological · Other
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Vail, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PENG Block for Arthroscopic Hip Surgery

NCT04508504
View directory record Official record
Conditions
Postoperative Pain, Hip Arthroscopy
Interventions
Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline
Procedure · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 4, 2026, 8:52 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

NCT07526974
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • Aventura, Florida • Alpharetta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 4, 2026, 8:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

NCT06857955
View directory record Official record
Conditions
Hypertension
Interventions
Saline, QCZ484
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
64
States / cities
Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 2 Interventional Results available

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

NCT01990768
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 4, 2026, 8:52 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 4, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

Ketamine to Prevent PPD After Cesarean

NCT04227704
View directory record Official record
Conditions
Postpartum Depression
Interventions
Ketamine 50 MG/ML, Control
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 4, 2026, 8:52 PM EDT